Total Payments
$1,930
2024 Payments
$33.88
Companies
11
Transactions
27
Medicare Patients
1,615
Medicare Billing
$320,319
Payment Breakdown by Category
Food & Beverage$1,787 (92.6%)
Education$142.99 (7.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,787 | 25 | 92.6% |
| Education | $142.99 | 2 | 7.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $436.95 | 8 | $0 (2020) |
| Merck Sharp & Dohme Corporation | $344.14 | 6 | $0 (2019) |
| Astellas Pharma US Inc | $252.01 | 4 | $0 (2017) |
| Gilead Sciences Inc | $240.22 | 2 | $0 (2017) |
| Insmed, Inc. | $130.09 | 1 | $0 (2019) |
| Melinta Therapeutics, Inc. | $124.65 | 1 | $0 (2018) |
| TETRAPHASE PHARMACEUTICALS, INC. | $121.36 | 1 | $0 (2019) |
| Shire North American Group Inc | $114.36 | 1 | $0 (2018) |
| The Medicines Company | $109.42 | 1 | $0 (2017) |
| Stryker Corporation | $33.88 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $33.88 | 1 | Stryker Corporation ($33.88) |
| 2023 | $22.89 | 1 | IBSA Pharma Inc. ($22.89) |
| 2020 | $125.00 | 1 | Allergan, Inc. ($125.00) |
| 2019 | $496.54 | 4 | Insmed, Inc. ($130.09) |
| 2018 | $299.24 | 3 | Melinta Therapeutics, Inc. ($124.65) |
| 2017 | $952.42 | 17 | Astellas Pharma US Inc ($252.01) |
All Payment Transactions
27 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/27/2024 | Stryker Corporation | ASNIS (Device) | Food and Beverage | In-kind items and services | $33.88 | General |
| Category: TRAUMA & EXTREMETIES | ||||||
| 08/07/2023 | IBSA Pharma Inc. | LICART (Drug), TIROSINT, TIROSINT | Food and Beverage | Cash or cash equivalent | $22.89 | General |
| Category: non-opioid analgesic | ||||||
| 02/25/2020 | Allergan, Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/21/2019 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $130.09 | General |
| Category: Respiratory | ||||||
| 10/22/2019 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/23/2019 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $120.09 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/25/2019 | TETRAPHASE PHARMACEUTICALS, INC. | Xerava (Drug) | Food and Beverage | In-kind items and services | $121.36 | General |
| Category: Complicated Intra-Abdominal Infections | ||||||
| 08/23/2018 | Melinta Therapeutics, Inc. | Vabomere (Drug) | Food and Beverage | Cash or cash equivalent | $124.65 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 04/11/2018 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $60.23 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/06/2018 | Shire North American Group Inc | CINRYZE (Drug) | Food and Beverage | In-kind items and services | $114.36 | General |
| Category: IMMUNOLOGY | ||||||
| 11/16/2017 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $113.60 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/24/2017 | The Medicines Company | VABOMERE (Drug) | Food and Beverage | In-kind items and services | $109.42 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/31/2017 | Astellas Pharma US Inc | Cresemba (Drug), Mycamine, Ambisome | Food and Beverage | In-kind items and services | $17.13 | General |
| Category: Infectious Diseases | ||||||
| 05/17/2017 | Allergan Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $17.80 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/03/2017 | Astellas Pharma US Inc | — | Education | In-kind items and services | $43.99 | General |
| 04/24/2017 | Allergan Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $18.69 | General |
| Category: ANTI-INFECTIVE | ||||||
| 03/31/2017 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.00 | General |
| 03/23/2017 | Allergan Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $95.60 | General |
| Category: ANTI-INFECTIVE | ||||||
| 03/22/2017 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $17.82 | General |
| Category: ANTI-INFECTIVE | ||||||
| 03/16/2017 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $91.89 | General |
| Category: Infectious Diseases | ||||||
| 02/28/2017 | Gilead Sciences Inc | — | Food and Beverage | In-kind items and services | $124.97 | General |
| 02/22/2017 | Merck Sharp & Dohme Corporation | NOXAFIL (Drug), DIFICID | Food and Beverage | In-kind items and services | $16.93 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/21/2017 | Gilead Sciences Inc | Descovy (Drug) | Food and Beverage | In-kind items and services | $115.25 | General |
| Category: HIV | ||||||
| 02/21/2017 | Merck Sharp & Dohme Corporation | ISENTRESS (Drug) | Food and Beverage | In-kind items and services | $17.39 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/09/2017 | Merck Sharp & Dohme Corporation | ZEPATIER (Drug) | Food and Beverage | In-kind items and services | $15.90 | General |
| Category: INFECTIOUS DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 473 | 1,007 | $225,340 | $80,942 |
| 2022 | 3 | 417 | 1,251 | $238,660 | $92,606 |
| 2021 | 3 | 369 | 941 | $184,680 | $72,380 |
| 2020 | 3 | 356 | 986 | $185,160 | $74,391 |
Total Patients
1,615
Total Services
4,185
Medicare Billing
$320,319
Procedure Codes
12
All Medicare Procedures & Services
12 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 245 | 760 | $133,000 | $49,210 | 37.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 137 | 152 | $63,840 | $21,564 | 33.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 91 | 95 | $28,500 | $10,168 | 35.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 229 | 1,041 | $156,700 | $61,039 | 39.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 144 | 158 | $66,360 | $25,776 | 38.8% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 44 | 52 | $15,600 | $5,790 | 37.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 178 | 726 | $108,900 | $43,175 | 39.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 83 | 90 | $37,560 | $15,029 | 40.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 108 | 125 | $38,220 | $14,176 | 37.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 177 | 784 | $117,600 | $47,586 | 40.5% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 126 | 144 | $43,200 | $16,866 | 39.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 53 | 58 | $24,360 | $9,938 | 40.8% |
About Dr. Steven Garcia, DO
Dr. Steven Garcia, DO is a Infectious Disease healthcare provider based in Lauderhill, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/25/2012. The National Provider Identifier (NPI) number assigned to this provider is 1235497520.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Steven Garcia, DO has received a total of $1,930 in payments from pharmaceutical and medical device companies, with $33.88 received in 2024. These payments were reported across 27 transactions from 11 companies. The most common payment nature is "Food and Beverage" ($1,787).
As a Medicare-enrolled provider, Garcia has provided services to 1,615 Medicare beneficiaries, totaling 4,185 services with total Medicare billing of $320,319. Data is available for 4 years (2020–2023), covering 12 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Lauderhill, FL
- Active Since 04/25/2012
- Last Updated 03/15/2019
- Taxonomy Code 207RI0200X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1235497520
Products in Payments
- ZERBAXA (Drug) $293.92
- DALVANCE (Drug) $220.60
- AVYCAZ (Drug) $161.91
- Arikayce (Drug) $130.09
- Vabomere (Drug) $124.65
- Xerava (Drug) $121.36
- Descovy (Drug) $115.25
- CINRYZE (Drug) $114.36
- VABOMERE (Drug) $109.42
- Cresemba (Drug) $109.02
- TEFLARO (Drug) $54.44
- ASNIS (Device) $33.88
- LICART (Drug) $22.89
- ISENTRESS (Drug) $17.39
- NOXAFIL (Drug) $16.93
- ZEPATIER (Drug) $15.90
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.